20:50 , Mar 2, 2018 |  BC Week In Review  |  Clinical News

Arca reports Phase IIb data for Gencaro in heart failure patients

Arca biopharma Inc. (NASDAQ:ABIO) reported top-line data from the Phase IIb GENETIC-AF trial in 267 heart failure patients with reduced left ventricular ejection fraction (LVEF) showing that Gencaro bucindolol hydrochloride led to a "similar treatment...
07:00 , Jun 15, 2015 |  BC Week In Review  |  Financial News

Arca biopharma completes private placement of units

Arca biopharma Inc. (NASDAQ:ABIO), Broomfield, Colo.   Business: Cardiovascular   Date completed: 2015-06-11   Type: Private placement of units   Raised: $37 million   Units: 42 million   Price: $0.88 (unit)   Shares after offering:...
07:00 , Apr 27, 2015 |  BC Week In Review  |  Clinical News

Gencaro bucindolol regulatory update

FDA granted Fast Track designation to Arca’s Gencaro bucindolol to prevent atrial fibrillation/atrial flutter in patients with reduced left ventricular ejection fraction (LVEF). The non-selective beta blocker and mild vasodilator is in Phase IIb/III testing...
08:00 , Dec 8, 2014 |  BC Week In Review  |  Company News

Arca biopharma management update

ARCA biopharma Inc. (NASDAQ:ABIO), Broomfield, Colo.   Business: Cardiovascular   Departing: Patrick Wheeler as CFO, effective Dec. 31   Promoted: Thomas Keuer, EVP of pharmaceutical operations, to COO  ...
07:00 , Jun 16, 2014 |  BC Week In Review  |  Company News

Arca biopharma board of directors update

Arca biopharma Inc. (NASDAQ:ABIO), Broomfield, Colo.   Business: Cardiovascular   Appointed: Robert Conway, a director, as chairman  ...
07:00 , Apr 21, 2014 |  BC Week In Review  |  Clinical News

Gencaro bucindolol: Phase IIb/III started

Arca began the double-blind, placebo-controlled, U.S. Phase IIb/III GENETIC-AF trial to compare 6.25, 12.5, 25, 50 and 100 mg oral Gencaro twice daily vs. 25, 50, 100 and 200 mg oral Toprol-XL metoprolol succinate twice...
07:00 , Apr 14, 2014 |  BC Week In Review  |  Financial News

Arca biopharma financial update

Arca filed a shelf registration covering the sale of up to $75 million of its securities. The company, which closed Friday at $1.72, has 21 million shares outstanding. Arca biopharma Inc. (NASDAQ: ABIO), Broomfield, Colo....
07:00 , Apr 7, 2014 |  BioCentury  |  Finance

2Q14 Financial Markets Preview: Minor adjustment

Biotech enters 2Q14 facing its second-largest correction since the beginning of the bull run in 2009. However, buysiders believe the worst of the pullback is in the rearview mirror and expect the equity markets will...
08:00 , Feb 27, 2014 |  BC Innovations  |  Targets & Mechanisms

The XII factor

Factor XII sits atop one branch of the clotting cascade but has not been pursued for treating and preventing thrombosis because it was seen as a minor player in blood coagulation. Now, a group from...
08:00 , Feb 10, 2014 |  BC Week In Review  |  Financial News

Arca biopharma completes follow-on

Arca biopharma Inc. (NASDAQ: ABIO), Broomfield, Colo.   Business: Cardiovascular   Date completed: 2/4/14   Type: Follow-on   Raised: $8.7 million   Shares: 5.1 million   Price: $1.70   Shares after offering: 20.8 million  ...